Article Menu
Need Help?
No Article Versions Notes Found
Cite
Tan, A.D.; Willemsma, K.; MacNeill, A.; DeVries, K.; Srikanthan, A.; McGahan, C.; Hamilton, T.; Li, H.; Blanke, C.D.; Simmons, C.E. Tyrosine Kinase Inhibitors Significantly Improved Survival Outcomes in Patients with Metastatic Gastrointestinal Stromal Tumour: A Multi-Institutional Cohort Study. Curr. Oncol. 2020, 27, 276-282. https://doi.org/10.3747/co.27.5869
Tan AD, Willemsma K, MacNeill A, DeVries K, Srikanthan A, McGahan C, Hamilton T, Li H, Blanke CD, Simmons CE. Tyrosine Kinase Inhibitors Significantly Improved Survival Outcomes in Patients with Metastatic Gastrointestinal Stromal Tumour: A Multi-Institutional Cohort Study. Current Oncology. 2020; 27(3):276-282. https://doi.org/10.3747/co.27.5869
Chicago/Turabian StyleTan, A. Deruchie, K. Willemsma, A. MacNeill, K. DeVries, A. Srikanthan, C. McGahan, T. Hamilton, H. Li, C.D. Blanke, and C.E. Simmons. 2020. "Tyrosine Kinase Inhibitors Significantly Improved Survival Outcomes in Patients with Metastatic Gastrointestinal Stromal Tumour: A Multi-Institutional Cohort Study" Current Oncology 27, no. 3: 276-282. https://doi.org/10.3747/co.27.5869
APA StyleTan, A. D., Willemsma, K., MacNeill, A., DeVries, K., Srikanthan, A., McGahan, C., Hamilton, T., Li, H., Blanke, C. D., & Simmons, C. E. (2020). Tyrosine Kinase Inhibitors Significantly Improved Survival Outcomes in Patients with Metastatic Gastrointestinal Stromal Tumour: A Multi-Institutional Cohort Study. Current Oncology, 27(3), 276-282. https://doi.org/10.3747/co.27.5869
